筛查子痫前期的早期标志物—胎盘蛋白13

Maternal Serum Placental Protein 13 as a Potential Marker for Early Pre-eclapsia

探讨早期筛查子痫前期高危人群的预测手段。系统分析胎盘蛋白13(PP13)在妊娠各期母体血清中含量变化规律。PP13是迄今发现的56种广泛分布于胎盘组织的胎盘蛋白质之一,与β-半乳糖结合蛋白家族具有高度的同源性。随妊娠进展,PP13在母体血清中含量缓慢上升,妊娠中晚期发生子痫前期的妇女,血清PP13含量早在妊娠6～13周显著降低,与正常妊娠妇女血清PP13含量呈明显差异。于妊娠11～13周检测PP13可筛查出妊娠中晚期子痫前期患者,准确率高达90%,与妊娠中晚期子痫前期有良好相关性。作为早期预测子痫前期潜在标志物,PP13对低风险妊娠妇女子痫前期早期筛查有十分重要的临床价值和应用前景。

To evaluate first-trimester maternal serum placental protein 13 as a screening test for preeclampsia （PE）. In prospective nested case-control studies, PP13 levels were measured during 1^st, 2^nd and 3^nd trimesters in women who developed PE vs matched controls. Placental protein 13 （PP13） is a 32-kd dimer protein produced only in the placenta which belongs to one of 56 members in one super family. PP13 is thought to be involved in normal implantation. As pregnancy progresses the level of PP13 in maternal serum slowly rises. The PP13 values in women who went to develop late-onset PE were lower in 1^st trimester （11-13） weeks but continuously increased to exceed the level of unaffected women in the 3^rd trimester. PP13 has been found to be a useful marker at 6-13 weeks of pregnancy for early serum screening to assess the risk to develop preeclampsia.